MetrioPharm Investor-Update QIV 2024
Dear shareholders,
I hope you have had a good year 2024. For MetrioPharm, it began with gratifying news: the renowned scientific journal Lancet Regional Health – Europe published data from our Phase IIa study on the successful treatment of hospitalized COVID-19 patients with our lead compound MP1032.
Our milestones from the COVID-19 trial
An average of 2.4 days earlier discharge from hospital, 4 days shorter ICU stay and faster recovery after 14 days of treatment with MP1032 were very good results for MP1032 in our COVID-19 trial, which was largely funded by an EU grant.
Although interest in COVID-19 therapeutics has waned noticeably, Lancet Regional Health – Europe was nonetheless particularly interested in MP1032's host-directed mechanism of action.
This innovative mechanism enables early action against new or mutated viruses without the need to develop specific antiviral drugs against them. This potential could revolutionize global pandemic preparedness. We plan to continue the costly development of this and other potential uses of MP1032 in indications with large patient populations – such as long COVID – with the help of additional grants.
Focus on rare diseases: Duchenne muscular dystrophy (DMD)
Our development efforts remain focused on rare diseases. We aim to use this fast and relatively cost-effective approach to bring MP1032 to a preliminary market authorization decision by the EMA and accelerated approval by the FDA.
For DMD, we have made significant progress in 2024 in advancing the preclinical development program. DMD patients are very young, and conducting a pediatric study is associated with high regulatory standards and corresponding pre-clinical studies. This is how we can ensure the safe use of MP1032 in pediatric patients. Some of these studies are still ongoing and we will be able to report results next year. So far, all these studies are proceeding according to plan.
In addition, the development and production of the investigational drug has been advanced in order to provide clinical investigational drugs for the planned study.
Preparations for the clinical trial itself are continuing concurrently. An important factor for success will be the recruitment of patients. In order to prepare this process at an early stage, MetrioPharm has intensified its already very good contact with the DMD community and met with patient organizations, physicians, and the teams of study centers. We have also initiated the selection process for a contract research organization (Clinical Research Organization, CRO). More than 30 CROs have applied to implement the study and the selection process is almost complete.
We were supported in all these activities by the members of our scientific advisory board, consisting of renowned scientific opinion leaders. They have contributed their profound expertise to help us tremendously: from the effect of our molecule on specific pathologies to advice on the ideal study design as seen by practicing specialists, their input was essential to the optimal preparation of the upcoming clinical trial. We at MetrioPharm are extremely grateful for this and look forward to tackling the tasks of the coming months together with our advisors. Of course, we would also like to thank our shareholders for their trust and, last but not least, the employees and members of the MetrioPharm Board of Directors.
Outlook 2025: Financing and further development
An important goal for the near future will be a further investment round in 2025. MetrioPharm is currently well funded, but given the still difficult financing climate, we need to ensure that sufficient funding for the development of MP1032 is secured.
We will continue to keep you informed about the progress on these projects.
 |
We wish you and your families a restful holiday season and a happy and healthy year 2025. With best regards |
MetrioPharm AG Company Calendar 2025
11-12 January: Longwood Healthcare Leaders Conference at JPMorgan Healthcare Conference, San Francisco, USA
13-15 January: Biotech Showcase at JP Morgan Healthcare Conference, San Francisco, USA
14 January: Annual Wuxi Global Forum 2025 at JP Morgan Healthcare Conference, San Francisco, USA
14-17 January: PPMD Duchenne Healthcare Provider Summit, San Diego, USA
16-19 March: Muscular Dystrophy Association Clinical & Scientific Conference, Dallas, USA
17-19 March: Bio-Europe Spring, Milan, Italy
28-29 March: Duchenne UK New Horizons Conference, London, UK
05-06 May: Swiss Biotech Day 2025, Basel, Switzerland
16-19 June: BIO International Convention, Boston, USA
19-21 June: Parent Project Muscular Dystrophy (PPMD) Annual Conference, Las Vegas, USA
MetrioPharm AG informs
MetrioPharm uses various channels to inform its shareholders:
Alongside the quarterly newsletter, we also keep you up to date on current developments in the company with press releases.
If you have not yet been included in our press mailing list, please send us an e-mail to invest@metriopharm.com.
Please feel free to network with us via LinkedIn.
We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments.
Your contact:
MetrioPharm
Investor Relations
T + 41 44 552 7190
E invest@metriopharm.com
W www.metriopharm.com